DUBLIN, Sept. 11, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Age-Related Macular Degeneration (AMD) Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
AMD is defined as the deterioration of the eye's macula. The macula is a small area in the retina that is responsible for central vision. The exact etiology of AMD is unknown. There are two types of macular degeneration: wet and dry. Wet AMD occurs when tiny abnormal blood vessels begin growing behind the retina toward the macula. Dry AMD occurs when small, yellowish deposits called drusen begin accumulating beneath the macula. While a number of treatments are available for wet AMD, there is no treatment available at the moment for dry AMD.
The analysts forecast the Global AMD market will grow at a CAGR of 6.62 percent over the period 2013-2018.
The Global AMD market can be divided into two segments: Dry AMD and Wet AMD. This report covers the present scenario and the growth prospects of the Global AMD market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of AMD.
The report, the Global AMD Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global AMD market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The acceptability of therapies used in the treatment of AMD is expected to rise because of increasing public awareness of AMD and the need for treatment. Increasing public awareness of AMD has led to an increase in physician and patient acceptance for AMD treatment options. For instance, February is the National AMD and Low Vision Awareness Month. This program encourages Americans above the age of 60 to learn the warning signs of AMD and schedule an annual dilated eye examination.
In honor of AMD Awareness Month, EyeCare America, which is a foundation of the American Academy of Opthalmology, has launched an AMD EyeCare Program. This year-round program promotes annual eye examinations for people aged 65 and over, raises awareness of AMD, provides the latest information about treatment options and low vision services, and offers free AMD educational materials.
According to the report, one of the main drivers is the increase in the aging population. More elderly patients are presenting with AMD disorders. With the increase in the aging population, the demand for AMD drugs is also increasing.
Further, the report states that one of the main challenges is the increase in off-label use. The off-label use of Avastin in the treatment of AMD will slow down market growth during the forecast period.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Product Portfolio of Current AMD Therapies
08. Clinical Pipeline Portfolio
09. Rate of Incidence and Prevalence
10. Market Segmentation by Types
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Other Reports in this Series
Companies Mentioned:
- Bayer AG
- F. Hoffmann-La Roche
- Novartis AG
- Regeneron Pharmaceuticals
- Acucela
- Advanced Cell Technology
- Alexion Pharmaceuticals
- Alimera Sciences
- Allergen
- Allergo Opthalmics
- Avalanche Biotechnologies
- Gilead Sciences
- GlaxoSmithKline
- Icon Bioscience
- Intellect Neurosciences
- Lpath
- Neurotech Pharmaceuticals
- Opthotech
- OSI Pharmaceuticals
- Oxigene
- PanOptica
- Pfizer
- Santen Pharmaceutical
- StemCells
- Synthetic Biologics
- Thrombogenics NV
- Valeant Pharmaceuticals International
For more information visit http://www.researchandmarkets.com/research/7t8ntp/global
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
